Outlook Therapeutics price to book ratio OTLK

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 39.2×; Aug 2023
10-year median: 18.8×
10-year range: 5.9× to 114×
Peer median: 2.5×

Outlook Therapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2023, at 39.2×.

On the days it had one over the last ten years, its median was 18.8×, from 5.9× in Jun 2022 to 114× in Feb 2021.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	39.2×	16.3×	44.3×
2022	28.2×	5.9×	67.2×
2021	66.2×	18.3×	114×
2020	58.5×	7.1×	69.8×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	34.0×	27.6×	76.6×

Against its peers

Companies in Healthcare nearest Outlook Therapeutics' size, closest first, today.

Company	Price to book ratio
OTLKOutlook Therapeutics	n/m
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
NATRNatures Sunshine Products	1.3×
LFVNLifevantage	2.2×
ELMDElectromed	4.1×
UTMDUtah Medical Products	1.9×
SPROSpero Therapeutics	1.5×
INFUInfuSystem	4.7×
Peer median	2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Outlook Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.